Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b adaptive study of safety , tolerability, and pharmacokinetics and pharmacodynamics of AST-004 in healthy volunteers

Next Previous
X
Search
Trial Profile

A phase 1b adaptive study of safety , tolerability, and pharmacokinetics and pharmacodynamics of AST-004 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AST-004 (Primary)
  • Indications Stroke; Traumatic brain injuries
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 29 Mar 2024 Results assessing the Safety, Tolerability and Plasma and Cerebrospinal Fluid Pharmacokinetics of Ast-004 after Intravenous Infusion in Healthy Volunteers presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 12 Mar 2024 According to an Astrocyte Pharmaceuticals media release, the company has been completed this and another phase 1 safety study in Europe involving 80 participants in total.
    • 12 Mar 2024 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top